ConductScience.org, home
786-O
API referenceFor AI assistants

Cell line · CVCL_1051

Papers166

2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.

1 to 20 of 166

Download this page as JSON
PaperJournalYearHow we knowRetractedSource
Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers.Mol Oncol2026Its Methods give the RRID and name the linePubMed
Inhibition of PLK1 helps to restrict c-Met-induced growth and therapeutic resistance of renal cancer cells.Mol Cancer Ther2026Its Methods give the RRID and name the linePubMed
Reduced VEPH1 expression is associated with an invasive phenotype and poor prognosis in clear cell renal cell carcinoma.Transl Androl Urol2026Its Methods give the RRID and name the linePubMed
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.Clin Cancer Res2026Its Methods give the RRID and name the linePubMed
Tumor-Induced PDPN+ Lymphatic-like Endothelial Cells Promote Clear-Cell Renal Cell Carcinoma Progression Through Reciprocal BMP10-CXCL13 Signaling.Int J Mol Sci2026Its Methods give the RRID and name the linePubMed
Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment.bioRxiv2026Its Methods give the RRID and name the linePubMed
RIOK2 Promotes Clear Cell Renal Cell Carcinoma Progression Through Cell Cycle Regulation.Cancer Med2026Its Methods give the RRID and name the linePubMed
Predicting Poor Efficacy of Cabozantinib in Advanced Renal Cell Carcinoma by Exploratory Metabolic Pathway Analysis and In Vitro Verification.Cancer Med2026Its Methods give the RRID and name the linePubMed
ALYREF-mediated m5C modification of CCNA1 drives escape from cell-cycle arrest and contributes to pazopanib resistance in Renal Cell Carcinoma.Int J Biol Sci2026Its Methods give the RRID and name the linePubMed
Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8+ T-cell activation.BMC Med2026Its Methods give the RRID and name the linePubMed
Targeting the ATX-LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways.Adv Sci (Weinh)2026Its Methods give the RRID and name the linePubMed
IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model.iScience2026Its Methods give the RRID and name the linePubMed
Hypoxia-induced PLOD3 activates the NEDD4/GOT2 axis to exacerbate renal cell carcinoma progression.Cell Death Dis2026Its Methods give the RRID and name the linePubMed
Integrating Bulk and Single-Cell RNA-Seq Reveals Glycolysis-Associated Macrophages and Its Related Tumor Subgroup Signatures to Predict Prognosis and Therapy in Clear Cell Renal Cell Carcinoma.Hum Mutat2026Its Methods give the RRID and name the linePubMed
An Integrated Immunometabolic Signature Predicts Prognosis and Immunotherapy Response in ccRCC and Identifies UCN-Mediated Immune Evasion as a Therapeutic Vulnerability: Evidence from In Vitro and In Vivo Studies.
Cancers (Basel)2026Its Methods give the RRID and name the linePubMed
USP18 promotes clear cell renal cell carcinoma progression by regulating the ubiquitination and stability of YBX3.iScience2026Its Methods give the RRID and name the linePubMed
Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation.Adv Sci (Weinh)2026Its Methods give the RRID and name the linePubMed
SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma.Cancer Res2026Its Methods give the RRID and name the linePubMed
Structure-guided optimization of SLC1A1/EAAT3-selective inhibitors targeting renal cancer metabolism.EMBO J2026Its Methods give the RRID and name the linePubMed
OSCAR functions as a collagen I receptor to suppress hippo signaling and reprogram lipid metabolism in clear-cell renal cell carcinoma.Cell Death Dis2026Its Methods give the RRID and name the linePubMed

cell-lines-2026-11-14-0.1.0

Next page

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_1051/papers

API referenceFor AI assistants